Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
LRMR
$6.0845
$
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Next Earnings
2026-02-25
Beta
1
Average Volume
Market Cap
Last Dividend
CIK
0001374690
ISIN
US5171251003
CUSIP
517125100
CEO
Carole S. Ben-Maimon
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
65
IPO Date
2014-06-19
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Laminar Therapeutics Stock Is Popping Today: What's Going On? | Larimar Therapeutics Inc (NASDAQ: LRMR) shares are jumping on Wednesday after multiple analysts reiterated their bullish outlook. | Benzinga | 2026-02-25 14:30:42 |
| Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation | The designation covers adults and children with the rare disease and was based on data from an ongoing open-label study. Here's what investors need to know. | Benzinga | 2026-02-24 12:12:40 |
| Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 | Nomlabofusp program granted Breakthrough Therapy Designation for the treatment of adults and children with FA based on FDA's review of available clinical data from open label study FDA written communications after recent START meeting continue to align with use of skin FXN to support BLA submission seeking accelerated approval Topline open label study data to support BLA submission expected in Q2 2026 Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved BALA CYNWYD, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to nomlabofusp, a frataxin (FXN) protein replacement therapy with disease modifying potential, for the treatment of adults and children with Friedreich's ataxia (FA). | GlobeNewsWire | 2026-02-24 07:00:00 |
| Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR) | Oncology Pharma (OTCMKTS:ONPH - Get Free Report) and Larimar Therapeutics (NASDAQ: LRMR - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Profitability This table compares Oncology Pharma and | Defense World | 2026-01-18 03:10:39 |
| Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care | Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich's Ataxia's root cause, with a mechanism that delivers missing frataxin, potentially supplanting current standard-of-care. Anaphylaxis concerns have been mitigated by new dosing protocols and FDA-approved trial modifications, positioning LRMR for a potential re-rating. | Seeking Alpha | 2026-01-16 06:17:31 |
| Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-14 14:36:00 |
| Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of “Moderate Buy” by Analysts | Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 12 month | Defense World | 2025-12-23 01:12:51 |
| Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. | GlobeNewsWire | 2025-12-18 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-24 | 2026-02-24 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-12 | 2026-02-12 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 8-K | 2026-01-22 | 2026-01-22 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2025-12-17 | 2025-12-17 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G/A | 2025-11-06 | 2025-11-06 | View Filing |
| 10-Q | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-11-05 | 2025-11-05 | View Filing |
| 8-K | 2025-10-14 | 2025-10-14 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| SC 13G | 2025-08-29 | 2025-08-29 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-04 | 2025-08-04 | View Filing |
| SC 13D/A | 2025-07-31 | 2025-07-31 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| 424B5 | 2025-07-31 | 2025-07-30 | View Filing |
| 8-K | 2025-07-29 | 2025-07-29 | View Filing |
| 424B5 | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| SC 13G | 2025-06-17 | 2025-06-17 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| 4 | 2025-05-14 | 2025-05-14 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-05 | 2025-05-05 | View Filing |
| 10-Q | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-30 | 2025-04-30 | View Filing |
| SC 13G/A | 2025-04-22 | 2025-04-22 | View Filing |
| SC 13G | 2025-04-16 | 2025-04-16 | View Filing |
| ARS | 2025-04-11 | 2025-04-11 | View Filing |
| DEF 14A | 2025-04-11 | 2025-04-11 | View Filing |
| S-8 | 2025-03-24 | 2025-03-24 | View Filing |
| 10-K | 2025-03-24 | 2025-03-24 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13G | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-27 | 2025-01-27 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 4 | 2025-01-24 | 2025-01-24 | View Filing |
| 8-K | 2025-01-10 | 2025-01-10 | View Filing |
| SC 13G/A | 2025-01-08 | 2025-01-08 | View Filing |
| 8-K | 2024-12-16 | 2024-12-16 | View Filing |
| 8-K | 2024-11-18 | 2024-11-18 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-06 | 2024-11-06 | View Filing |
| 10-Q | 2024-10-30 | 2024-10-30 | View Filing |
| 8-K | 2024-10-30 | 2024-10-30 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-07 | 2024-08-07 | View Filing |
| 8-K | 2024-06-10 | 2024-06-10 | View Filing |
| 4 | 2024-06-03 | 2024-06-03 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 4 | 2024-05-31 | 2024-05-31 | View Filing |
| 8-K | 2024-05-31 | 2024-05-31 | View Filing |
| 8-K | 2024-05-30 | 2024-05-30 | View Filing |
| EFFECT | 2024-05-24 | 2024-05-27 | View Filing |
| CORRESP | 2024-05-22 | 2024-05-22 | View Filing |
| 8-K | 2024-05-20 | 2024-05-20 | View Filing |
| UPLOAD | 2024-05-16 | 2024-05-16 | View Filing |
| S-3 | 2024-05-09 | 2024-05-09 | View Filing |
| 10-Q | 2024-05-09 | 2024-05-09 | View Filing |
| 8-K | 2024-05-09 | 2024-05-09 | View Filing |
| ARS | 2024-04-29 | 2024-04-29 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| PRE 14A | 2024-04-12 | 2024-04-12 | View Filing |
| SC 13D/A | 2024-03-15 | 2024-03-15 | View Filing |
| S-8 | 2024-03-14 | 2024-03-14 | View Filing |
| S-8 | 2024-03-14 | 2024-03-14 | View Filing |
| 10-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-11 | 2024-03-11 | View Filing |
| SC 13G | 2024-02-26 | 2024-02-26 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Larry Williams PercentR Strategy | 23.83% | 1.35 | 20 | 0.82 | 1.28 | 35.28 |
| Williams PercentR Strategy | 13.88% | 1.25 | 26 | 0.47 | 0.39 | 25.33 |
| VWAP | 11.82% | 0.98 | 39 | 0.39 | 0.34 | 23.26 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |